Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Deanne E. Knapp is active.

Publication


Featured researches published by Deanne E. Knapp.


Medical Care | 1988

Prescription drug use in 1984 and changes over time.

Carlene Baum; Dianne L. Kennedy; Deanne E. Knapp; John P. Juergens; Gerald A. Faich

More than 1.5 billion prescriptions were dispensed from retail pharmacies in 1984 at a consumer cost of


Annals of Pharmacotherapy | 1980

A method for post-marketing screening of adverse reactions to drugs: initial results.

Deanne E. Knapp; Brian B. Zax; Allen C. Rossi; Robert T. O'Neill

18.4 billion. The number of prescriptions dispensed in 1984 equaled the previous record set in 1973. Over 40% of 1984 prescriptions were for four therapeutic classes: cardiovascular drugs, anti-infectives, psychotherapeutic drugs, and diuretics. Prescriptions for cardiovascular drugs and diuretics increased substantially from 1975 to 1984, while prescriptions for psychotherapeutic drugs decreased. Outpatient use of systemic antiinfectives remained fairly stable over the 10-year period. Trends in the use of specific drug categories within these broad therapeutic classes were variable, as were patient age and sex distributions.


Annals of Pharmacotherapy | 1977

Drug use in Australia and the United States as Reflections of Legislation and Social Attitudes

David A. Knapp; Deanne E. Knapp; Geoffrey E. Brooks

The FDA is pilot-testing a methodology for signaling previously unsuspected relationships between drugs and important adverse events. This method uses data it receives through the FDA spontaneous reporting program. Reviewing drugs used primarily on an outpatient basis, this screening methodology focuses on “tracer” adverse events and the organization of these reactions into body/functional systems. This review process enables a clinical evaluator to perceive more easily the clinically important drug-adverse event patterns. The method can incorporate drug use data; this enables a drugs proportional share of specific adverse events, relative to its therapeutic class, to be compared to its respective proportional share of drug use. The assumption is that the adverse event distribution of drugs in a therapeutic class should be the same as the distribution of drug use in that class, if all drugs in the class were to carry the same risk. Actual examples of drug-adverse event associations signaled by the screening method are presented. The potential uses of this methodology in other settings, and under other data situations, are discussed.


JAMA | 1983

Discovery of Adverse Drug Reactions: A Comparison of Selected Phase IV Studies With Spontaneous Reporting Methods

Allen C. Rossi; Deanne E. Knapp; Charles Anello; Robert T. O'Neill; Cheryl Graham; Peter S. Mendelis; George R. Stanley

The opinions expressed in this paper are those of the authors and not necessarily those of their respective governments. attitudes. Drug use is defined as use in a legitimate, medical context; nonmedical uses of drugs or drug abuse are not considered. Three major aspects are examined: government controls over the distribution of drug products, economics of obtaining drugs and related pharmacy services, and factors affecting individual decisionmaking in prescribing.


JAMA | 1984

Discovery of New Adverse Drug Reactions: A Review of the Food and Drug Administration's Spontaneous Reporting System

Allen C. Rossi; Deanne E. Knapp


JAMA | 1987

National Adverse Drug Reaction Surveillance: 1985

Gerald A. Faich; Deanne E. Knapp; Michael W. Dreis; Wayne M. Turner


The American Journal of Pharmaceutical Education | 2009

Attributes of Colleges and Schools of Pharmacy in the United States

David A. Knapp; Deanne E. Knapp


Social Science & Medicine | 1968

Disillusionment in pharmacy students

Deanne E. Knapp; David A. Knapp


Journal of The American Pharmaceutical Association | 1977

Incorporating diagnosis information into a manual drug use review system.

David A. Knapp; Brenda M. Brandon; Deanne E. Knapp; Linda S. Klein; Francis B. Palumbo; Rohit Shah


Social Science & Medicine | 1970

Perceived credibility, expertise and effectiveness: pharmacist vs. physician

Deanne E. Knapp; David A. Knapp

Collaboration


Dive into the Deanne E. Knapp's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Charles Anello

Food and Drug Administration

View shared research outputs
Top Co-Authors

Avatar

Gerald A. Faich

Food and Drug Administration

View shared research outputs
Top Co-Authors

Avatar

Robert T. O'Neill

Food and Drug Administration

View shared research outputs
Top Co-Authors

Avatar

Carlene Baum

Food and Drug Administration

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Michael W. Dreis

Food and Drug Administration

View shared research outputs
Top Co-Authors

Avatar

Wayne M. Turner

Food and Drug Administration

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge